Skip to main content
Fig. 5 | Stem Cell Research & Therapy

Fig. 5

From: Development of a therapy against metastatic bladder cancer using an interleukin-2 surface-modified MB49 bladder cancer stem cells vaccine

Fig. 5

Antitumor potency of the SA-IL-2 MCSCs vaccine in the subcutaneous model mice. a In the cytotoxicity assay, the portion of CTL in the experimental group was significantly higher than in the four control groups. b In ELISA assay, the expression of serum IgG antibodies in the experimental group was significantly higher than in the four control groups. c FCM analysis showed that the portion of DCs (CD11c+CD80+) in the experimental group was significantly larger than in the four control groups. d FCM analysis showed that the portion of CD8+and CD4+ T cells in the experimental group was significantly larger than in the four control groups. *P < 0.05 (vs experimental group). SA-IL-2 streptavidin mouse interleukin-2, MCSCs MB49 bladder cancer stem cells, CTL cytotoxic T lymphocytes, ELISA enzyme-linked immunosorbent assay, IgG immunoglobulin G, FCM flow cytometry, DCs dendritic cells, PBS phosphate-buffered saline

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512